Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 4—April 2025
Research

Neutralizing Antibodies against California Serogroup Orthobunyaviruses in Human Serum Samples, Montana, USA

Tyson A. Woods1, Stephen F. Johnson1, Alyssa B. Evans2, and Karin E. PetersonComments to Author 
Author affiliation: Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA

Main Article

Figure 4

Numbers and percentages of positive samples in a study of neutralizing antibodies against California serogroup orthobunyaviruses in human serum samples, Montana, USA. A) Number of positive and negative samples among 694 tested (excluding samples that could not be analyzed by subsequent screening), 23% of all samples with neutralizing antibody responses. B) Percentage of each virus in 100 samples analyzed from the East region, regardless of their initial positivity to JCV. These samples were analyzed independently for neutralizing antibodies against LACV, CEV, JCV, SSHV, TVTV, and CVV; 60% of positive samples were for positive for JCV or CEV or dual positive for CEV and JCV. CEV, California encephalitis virus; CVV, Cache Valley virus; JCV, James Canyon virus; LACV, La Crosse virus; SSHV, snowshoe hare virus; TVTV, Trivittatus virus.

Figure 4. Numbers and percentages of positive samples in a study of neutralizing antibodies against California serogroup orthobunyaviruses in human serum samples, Montana, USA. A) Number of positive and negative samples among 694 tested (excluding samples that could not be analyzed by subsequent screening), 23% of all samples with neutralizing antibody responses. B) Percentage of each virus in 100 samples analyzed from the East region, regardless of their initial positivity to JCV. These samples were analyzed independently for neutralizing antibodies against LACV, CEV, JCV, SSHV, TVTV, and CVV; 60% of positive samples were for positive for JCV or CEV or dual positive for CEV and JCV. CEV, California encephalitis virus; CVV, Cache Valley virus; JCV, James Canyon virus; LACV, La Crosse virus; SSHV, snowshoe hare virus; TVTV, Trivittatus virus.

Main Article

1These first authors contributed equally to this article.

2Current affiliation: Department of Microbiology and Cell Biology, Montana State University, Bozeman, Montana, USA

Page created: February 08, 2025
Page updated: March 10, 2025
Page reviewed: March 10, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external